| Literature DB >> 29725071 |
Anna Roszkowska1,2, Miao Yu1, Vincent Bessonneau1, Leslie Bragg3, Mark Servos3, Janusz Pawliszyn4.
Abstract
Low-invasive in vivo solid-phase microextraction (SPME) was used to investigate the lipid profiles of muscle tissue of living fish. Briefly, mixed mode SPME fibers were inserted into the muscle for 20 min extraction, and then the fibers were desorbed in an optimal mixture of solvents. The obtained lipid profile was then compared and contrasted to that obtained with employment of ex vivo SPME and solid-liquid extraction (SLE) from fish muscle tissue belonging to the same group of fish, following a one-year storage period. Ex vivo SPME analysis of stored muscle samples revealed 10-fold decrease in the number of detected molecular features in comparison to in vivo study. Moreover, in vivo microsampling enabled the identification of different classes of bioactive lipids, including fatty acyls, not present in the lipid profile obtained through ex vivo SPME and SLE, suggesting the alterations occurring in the unbound lipid fraction of the system under study during the storage and also indicating the advantage of the in vivo extraction approach.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29725071 PMCID: PMC5934459 DOI: 10.1038/s41598-018-25428-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Histogram of mass distributions of detected peaks found in data obtained from (a) in vivo SPME of fish muscles in living fish; (b) ex vivo SPME analysis of non-homogenized fish tissue after a one-year storage period; and (c) solid-liquid extraction analysis of homogenized fish muscle samples after a one-year storage period.
Unique features with medium-to-high confidence matches annotated by LIPID MAPS.
| Compound | Category | Precursor m/z | Precursor adducts | RT (min) | Sample | Confidence match | ||
|---|---|---|---|---|---|---|---|---|
| SLE | ||||||||
| 2-decene-4,6,8-triyn-1-al | Fatty Acyls | 143.04856 | M + H | 0.80 | ✓ | high | ||
| N-eicosanoyl-ethanolamine | Fatty Acyls | 356.35235 | M + H | 8.10 | ✓ | medium | ||
| N-(11Z-eicosaenoyl)-ethanolamine | Fatty Acyls | 354.33658 | M + H | 8.45 | ✓ | medium | ||
| 4-[(5-aminopentyl)(hydroxy)amino]−4-oxobutanoic acid | Fatty Acyls | 219.13410 | M + H | 0.93 | ✓ | medium | ||
| N-octadecanoyl-valine | Fatty Acyls | 384.34715 | M + H | 8.97 | ✓ | medium | ||
| N-octadecanoyl-proline | Fatty Acyls | 382.33164 | M + H | 8.60 | ✓ | medium | ||
| 3-oxobutanamide | Fatty Acyls | 102.05523 | M + H | 0.90 | ✓ | ✓ | medium, high* | |
| hexadecanamide | Fatty Acyls | 256.26374 | M + H | 8.15 | ✓ | medium | ||
| pentanamide | Fatty Acyls | 102.09158 | M + H | 1.37 | ✓ | ✓ | medium | |
| Dodecanamide | Fatty Acyls | 200.20115 | M + H | 6.27 | ✓ | ✓ | medium | |
| O-(17-carboxyheptadecanoyl)carnitine | Fatty Acyls | 458.34762 | M + H | 7.62 | ✓ | medium | ||
| 3,7-dimethyl-8,11-dioxo-2E,6E,9E-dodecatrienal | Fatty Acyls | 235.13304 | M + H | 6.43 | ✓ | medium | ||
| 2-amino-hexanedioic acid | Fatty Acyls | 162.07614 | M + H | 0.93 | ✓ | medium | ||
| 2E,4E,8E,10E-dodecatetraenedioic acid | Fatty Acyls | 223.09658 | M + H | 6.10 | ✓ | medium | ||
| 7,8-diaminononanoic acid | Fatty Acyls | 189.15971 | M + H | 1.17 | ✓ | medium | ||
| 2-amino-3-oxo-hexanedioic acid | Fatty Acyls | 176.05533 | M + H | 0.90 | ✓ | medium | ||
| 12-amino-dodecanoic acid | Fatty Acyls | 216.19599 | M + H | 4.28 | ✓ | medium | ||
| 3-oxo-5S-amino-hexanoic acid OK | Fatty Acyls | 146.08116 | M + H | 0.87 | ✓ | ✓ | medium | |
| 10-hydroxy-8E-Decene-2,4,6-triynoic acid | Fatty Acyls | 177.05468 | M + H | 6.10 | ✓ | medium | ||
| 5,7,9,11,13-tetradecapentaenoic acid | Fatty Acyls | 219.13809 | M + H | 5.95 | ✓ | medium | ||
| octadecanamide | Fatty Acyls | 284.29440 | M + H | 8.85 | ✓ | ✓ | medium, high* | |
| N-(9Z,12Z-octadecadienoyl)-ethanolamine | Fatty Acyls | 324.28921 | M + H | 7.98 | ✓ | high | ||
| 3-(heptanoyloxy)−4-(trimethylazaniumyl)butanoate | Fatty Acyls | 274.20109 | M + H | 3.03 | ✓ | high | ||
| 3-{[(5Z)−3-hydroxyoct-5-enoyl]oxy}−4-(trimethylazaniumyl)butanoate | Fatty Acyls | 302.19547 | M + H | 4.19 | ✓ | high | ||
| 3-[(2E)-hex-2-enoyloxy]−4-(trimethylazaniumyl)butanoate | Fatty Acyls | 258.17035 | M + H | 5.43 | ✓ | high | ||
| 2,4,6-octatrienal | Fatty Acyls | 123.08059 | M + H | 5.34 | ✓ | high | ||
| 12-chloro-dodecanoic acid | Fatty Acyls | 235.14579 | M + H | 5.90 | ✓ | high | ||
| methyl 4-[2-(2-formyl-vinyl)−3-hydroxy-5-oxo-cyclopentyl]-butanoate | Fatty Acyls | 255.12251 | M + H | 7.40 | ✓ | high | ||
| (5Z,7E)−9,10-seco-5,7,10(19)-cholestatriene | Sterol Lipids | 369.35150 | M + H | 10.52 | ✓ | ✓ | high | |
| 26,26,26-trifluoro-25-hydroxy-27-norvitamin D3 | Sterol Lipids | 441.29831 | M + H | 10.42 | ✓ | medium | ||
| (6RS)−6,19-epidioxy-24,24-difluoro-25-hydroxy-6,19-dihydrovitamin D3 | Sterol Lipids | 469.31338 | M + H | 6.89 | ✓ | high | ||
| cholesta-5,7,8(14),22E-tetraen-3-one | Sterol Lipids | 379.30122 | M + H | 8.42 | ✓ | medium | ||
| (25 R)−3α,7α-dihydroxy-5β-cholestan-27-oyl taurine | Sterol Lipids | 542.35356 | M + H | 5.20 | ✓ | medium | ||
| 1-octadecanoyl-rac-glycerol | Glycerolipids | 359.31578 | M + H | 8.87 | ✓ | medium | ||
| 1-tetradecanoyl-glycero-3-phospho-(1-sn-glycerol) | Glycerophospholipids | 457.25547 | M + H | 9.00 | ✓ | high | ||
| 1-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-glycero-3-phosphoserine | Glycerophospholipids | 570.28281 | M + H | 6.86 | ✓ | high | ||
| 1-(1Z-eicosenyl)−2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-glycero-3-phosphoserine | Glycerophospholipids | 848.57957 | M + H | 10.47 | ✓ | high | ||
| 1-(7Z,10Z,13Z,16Z-docosatetraenoyl)-glycero-3-phosphocholine | Glycerophospholipids | 572.37175 | M + H | 7.72 | ✓ | high | ||
*For this compound, medium confidence match refers to in vivo SPME, high confidence match refers to SLE
The annotation was based on intensity profiles, retention time, mass defect, and isotope/adduct patterns of peaks. In high confidence match, non-zero xMSannotator multistage score, required adducts, N, O, P, S/C ratio check, hydrogen/carbon ratio check, abundance ratio checks for isotopes, multimers and multiply charged adducts are satisfied; in medium confidence match, pathway level correlation is satisfied[18].